Front Immunol 10: 2318

The Metabolic Requirements of Th2 Cell Differentiation

Promotion of Th2 Cell Differentiation by Mammalian Target of Rapamycin (mTOR)

In early and probably also later differentiation of T helper cells, coordination of cell growth, proliferation and metabolism is mediated by the kinase mTOR (57) (Figure 1). The mTOR complex monitors nutrient availability and integrates signals from growth factors and cytokine receptors to regulate glucose, amino acid and lipid metabolism. mTOR complex1 (mTORc1) is formed with the scaffolding protein regulatory associated protein of mTOR (RAPTOR) while mTOR complex 2 (mTORc2) uses Rapamycin-insensitive companion of mammalian target of rapamycin (RICTOR) as a scaffold (58). Differentiation toward the effector Th cell lineages Th1, Th2, and Th17 is known to be reliant on mTOR activity, while inhibition of mTOR with rapamycin has been shown to favor Treg cell differentiation (59–61). All effector lineages including Th2 cells have been shown to require mTORc1 activation, since deletion of RAPTOR and thereby mTORc1 potently inhibits effector differentiation (62).

An external file that holds a picture, illustration, etc.
Object name is fimmu-10-02318-g0001.jpg

Figure 1

Th2 cell differentiation requires extensive metabolic reprogramming. Upon encountering cognate antigen in the lymph node, naive CD4 T helper cells differentiate into Th2 cells under the influence of the IL-4-STAT6-GATA3 axis. Concurrently, changes in energy requirements occur as a Th2 cell differentiates, which requires an increase in glucose uptake via GLUT1 and marked upregulation of glycolysis. mTORc1 senses nutrient availability and co-ordinates metabolism in T helper cells, and mTORc2 promotes Th2 cell differentiation through several mechanisms. As Th2 cells enter inflamed tissue sites such as the lung, they continue to differentiate through exposure to a range of inflammatory cytokines including TSLP, IL-25, and IL-33 that promote production of effector cytokines such as IL-5, IL-9, and IL-13. In addition, PPAR-γ drives expression of lipid metabolic genes such as Fabp4 and Vdlr as well as genes critical to Th2 cell effector functions, such as ST2 (Il1rl1) and Il5. Extracellular metabolites present in the tissues including SCFA, ATP, and TRP can further promote Th2 cell differentiation and/or function. On the other hand, glutamine obtained from the diet potentiates Th1 cells at the expense of Th2 cells.

A number of studies have also highlighted a specific role for mTORc2 in Th2 cell differentiation. mTORc2 inhibits suppressor of cytokine signaling-5 (SOCS5) (63), which in turn suppresses IL-4-dependent STAT6 signaling to block Th2 cell differentiation (64). SGK1, a downstream target of mTORc2, promotes Th2 cell lineage commitment while blocking Th1 cell development (65). Furthermore, deletion of the GTPase RhoA, another mTORc2 target leads to decreased glycolysis and IL-4 production (66). Thus, while there is a clear requirement for mTORc1 in early Th2 cell development, signals downstream of mTORc2 seems to have distinct positive effects on the differentiation of Th2 cells.

Early Induction of Glycolysis in T helper Cells

Naïve T cells rely primarily on oxidative lipid metabolism as they recirculate among lymph nodes (51, 52). However, naïve T cells are poised for a rapid switch to effector cell metabolism by accumulating untranslated mRNAs required for glycolysis and fatty acid synthesis (67). Activation of T cells through the T cell receptor, co-stimulatory ligands and cytokine receptors is followed by expansion, differentiation and production of effector cytokines; processes which place a great metabolic pressure on cells.

Cells can upregulate glycolysis at faster rates than oxidative phosphorylation, as glycolysis requires no mitochondrial growth (47). The high rate of glycolysis in effector T cells requires activation of mTOR, HIF-1α and increased expression of glucose transporters like Glut1, which is essential for CD4 but not for CD8 T cells (68, 69). Glut1 is translocated to the cell surface upon activation, a process mediated through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway (70) and Myc expression (53). Glycolysis supports T cell activation in many ways; for instance by supporting epigenetic modifications through lactate dehydrogenase A (54) and by supplying dividing cells with many side products required for division and growth. Effector T helper cell subsets including Th1, Th2, and Th17 are all highly dependent on glycolysis for growth and function, and a small subset of Treg cells has also been shown to be highly glycolytic (61). Effector T helper cells have been shown to undergo various levels of glycolysis in in vitro assays and Th2 cells express the most Glut1 and appear the most glycolytic, when analyzed via Seahorse Analyzer (41, 51), suggestive of a more prominent role for the glycolytic machinery in these cells.

Fatty Acid Metabolism in Early T helper Cell Activation

A critical aspect of early T cell activation is the upregulation of lipid metabolism, especially lipid synthesis pathways, which enables cells to grow and divide. Typically, mTORc1 promotes lipid synthesis pathways by activating SREBP transcription factors (71). One of many targets of SREBPs is an enzyme essential in de novo synthesis of fatty acids, ACC1. In studies by Berod et al. (72), inhibition of ACC1 genetically or pharmaceutically prevented the differentiation of all effector lineages, while Treg cells preferentially differentiated from cultures of Th17 cells. This demonstrates that fatty acid synthesis is an essential feature of early T helper cell differentiation. In a separate study, it was suggested that early T helper cell activation, proliferation and growth may also rely on fatty acid uptake, orchestrated by the nuclear receptor, peroxisome proliferator activated receptor gamma (PPAR-γ) (73). However, the early division and proliferation of T helper cells was shown to be unaffected by genetic loss of PPAR-γ in another study (74) and the increase in PPAR-γ expression under neutral conditions is minor (73, 74). PPAR-γ becomes highly expressed specifically in Th2 cells and likely regulates fatty acid metabolism later in the Th2 cell differentiation program.

Inflammatory Cytokines in the Tissue Potentiate Th2 Cell Differentiation

Priming of CD4 T cells toward the Th2 cell subset in the lymph node induces the production of IL-4. However, several studies in the context of infection to N. brasiliensis and H. polygyrus, or to the allergen house dust mite (HDM) have shown that a large portion of IL-4-producing cells in these settings are Tfh cells (38, 75, 76). Full Th2 cell effector functions in the N. brasiliensis and HDM models, are not observed until T helper cells reach the lung tissue.

It is increasingly appreciated that the activation of epithelial and innate cells at the site of allergen, venom or pathogen entry plays an important role in shaping Th2 cell responses (77). Impaired barrier function, exposure to damage associated molecular patterns (DAMPs) and microbial products can trigger receptors like Toll Like Receptor-4 (TLR4) and Protease Activated Receptor-2 (PAR2) in epithelial and tuft cells that line the surface of the airways (78, 79). These cells as well as innate lymphoid cells (ILCs), macrophages and dendritic cells (DCs), in turn secrete a range of potent inflammatory cytokines including IL-1, IL-18, IL-25, IL-33, GM-CSF, M-CSF, and thymic stromal lymphopoietin (TSLP) (42, 77). In the case of DCs, cytokines such as TLSP and IL-33 can promote expression of OX40L and suppression of IL-12 which further promotes Th2 cell differentiation and function (80–85). These signals from epithelial cells and innate cells in the lung have been shown to contribute significantly to the final identity of Th2 cells in the tissue environment (41, 42).

Studies of infection with the helminth N. brasiliensis suggest that cytokines such as IL-25, IL-33, and TSLP are not required for the initial stages of Th2 cell differentiation within the lymph node but function to shape those “primed” Th2 effector cells upon entry to the inflamed sites such as the lung (42). Furthermore, our recent work depicted that activated T cells entering the lung were exposed to type I interferons in the context of HDM challenge, although how this cytokine may impact on Th2 cell functions remains unclear (41).

Comparison of the transcriptional and chromatin landscapes of lung Th2 cells to Th2 cells or naïve CD4 T cells from the lymph nodes demonstrated stark differences in lung Th2 cells (41, 42), suggesting that these cells more closely aligned with type 2 ILC (ILC2) from the lung than their lymph node counterparts (86). Thus, striking changes in cellular identity occur when T helper cells reach inflammatory tissues, and this is likely coupled with important metabolic changes.

Activation of Lipid Metabolism Pathways Is a Prominent Feature of Tissue Th2 Cells

A distinguishing feature of Th2 cells in the airways of mice administered HDM antigens was a striking upregulation in the expression of genes related to lipid oxidation and synthesis (41) (Figure 1). Comparison of DNA accessibility by ATAC-Sequencing also revealed more open chromatin at many gene loci associated with lipid metabolism in Th2 cells, compared with other T helper cell subsets in the lung, or naïve CD4 T cells in the lymph node (41). This feature of Th2 cells appears to be shared by ILC2 in the gut and lungs (87, 88). Using etomoxir and orlistat in vivo to block fatty acid oxidation, synthesis and uptake, Wilhelm and colleagues demonstrated that ILC2 were highly dependent on fatty acid metabolism both for their expansion and function (88). Similarly, blockade of these pathways in Th2 cell-mediated inflammation of the airways reduced Th2 cell pathologies such as airway eosinophilia and goblet cell metaplasia, and appeared to reduce T helper cell expansion and the production of IL-5 and IL-13 by Th2 cells to some extent (41).

PPAR-γ: Linking Th2 Cell Function and Cellular Metabolism

A feature of Th2 cells, ILC2, and alternatively activated M2 macrophages is the expression of PPAR-γ, a master regulator of adipocyte differentiation and regulator of lipid metabolism in various cell types (89–93). PPAR-γ belongs to a superfamily of nuclear receptors whose transcriptional effects are regulated by many natural ligands and dependent on co-factors such as CEBP, RXRα and other transcription factors (94). In macrophages and dendritic cells, PPAR-γ expression is induced by IL-4R ligation and STAT6 activation and it is likely the same mechanism at play in Th2 cells (95–97). The absence of PPAR-γ prevents the acquisition of the M2 phenotype, with impaired fatty acid uptake and mitochondria biogenesis (96, 98). The absence of PPAR-γ in CD4 T cells ameliorated Th2 cell-associated pathology in airway inflammation models and impaired Th2 cell-mediated immunity to H. polygyrus (91, 93). An important facet of this phenotype was that PPAR-γ appeared to be particularly important for the pathogenic phenotype of Th2 cells in the lung (91, 93). Early activation of Th2 cells in lung-draining lymph nodes did not appear to be greatly affected (91). This suggests that PPAR-γ becomes important in sensing ligands in inflamed tissue. It remains unclear how the loss of PPAR-γ impacts on ILC2, although its high expression specifically in this subset of ILC, and its important role in M2 macrophages and Th2 cells implies that it could be important for ILC2 functions.

PPAR-γ Directly Promotes Th2 Cell Functions

The impact of PPAR-γ on the expression of the early Th2 cell effector cytokine IL-4 is ambiguous. Studies have characterized that the absence of PPAR-γ reduces (93), increases (74) or has no effect (91) on CD4 T cell-derived IL-4, thus making it apparent that the impact of PPAR-γ on IL-4 production is context and assay dependent. A clearer impact of PPAR-γ has been demonstrated for features of Th2 cells in lung tissue. For instance, the absence of PPAR-γ in CD4 T cells impairs the expression of ST2 in lung and airway Th2 cells, and significantly impairs the expression of IL-5 and IL-13 by CD4 T cells (91). In humans, PPAR-γ is highly expressed in CRTH2^{Th2 cells thought to harbor the pathogenic Th2 cell subset (}93). It has also been linked to IL-9 production by a subset of pathogenic Th2 cells, which are prevalent in lesions taken from the skin of contact dermatitis patients (99). Inhibition of PPAR-γ profoundly suppressed the frequency of IL-9^{Th2 cell clones.}

Mechanistic studies have pinpointed an enrichment for PPAR-γ binding sites at open chromatin regions in Th2 cells (41), and chromatin immunoprecipitation-sequencing (CHIP-Seq) has identified a number of critical target genes for PPAR-γ binding including Ap1, Ets1, Runx1, Gata3, Stat5, Il5, and Il13 (100). Since PPAR-γ is a potent repressor as well as activator of gene transcription, it is difficult to predict the impact of this nuclear receptor through CHIP-Seq and ATAC-Seq analysis. Our own work demonstrated that the addition of PPAR-γ ligands to in vitro cultures had little direct impact on effector cytokine production by Th2 cells, but potently upregulated ST2 expression (91). For instance, the prostaglandin derivative 15dΔ12,14- PGJ₂ (15d-PGJ₂) was able to induce ST2 expression, as did synthetic agonists such as pioglitazone (101, 102), a member of the class of clinically-approved compounds known as thiazoldinediones (TZDs). Thus, PPAR-γ plays an important role in shaping the chromatin architecture of Th2 cells and appears particularly important for late stage effector functions of Th2 cells.

A Role for PPAR-γ in Modulating Th2 Cell Metabolism

While PPAR-γ is a well-characterized regulator of cellular metabolism in macrophages, dendritic cells, tumor cells and adipocytes (103–105), its impact on Th2 cell metabolism is less well-understood. In co-operation with STAT6, PPAR-γ is thought to regulate lipid metabolism in DC and macrophages through the regulation of genes including Fabp4 (97).

In Th2 cells, arrays of PPAR-γ-deficient ST2^{T helper cells suggested that a range of metabolic pathways may be affected by the absence of PPAR-γ including carbohydrate synthesis, metabolite transport, lipid storage and lipolysis (}91). However, these gene expression arrays are complicated by the fact that ST2^{Th2 cells have difficulty differentiating into fully pathogenic Th2 cells. In the study by Angela and colleagues, PPAR-γ was shown to be induced by mTORc1 activation and particular important for the expression of genes associated with fatty acid uptake and lipolysis including}Ldlr, Scrab2, Vdlr, Plin2, and Fabp5 (73). In this study, silencing of PPAR-γ impaired oxidative metabolism and glycolysis suggesting that PPAR-γ may not only promote lipid metabolism.

Thus, PPAR-γ plays important roles in promoting the expression of critical Th2 cell-associated factors such as ST2, but also likely contributes to regulating the lipid metabolism in these cells, especially in the tissue context. More mechanistic studies are required to dissect the impact of PPAR-γ on cellular metabolism in T cells, potentially in the context of overexpression systems.

Glycolysis and Th2 Effector Cell Function in situ

Glycolysis is not only important in the early phases of T cell activation but may also play a direct role in shaping T cell effector functions in inflamed tissues such as the lung. Active glycolysis has been shown to promote production of IFN-γ by Th1 cells and CD8 T cells in vitro and in the tumor microenvironment (106, 107). In the absence of active glycolysis, the enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) bound the 3'UTR of Ifng mRNA, impeding its translation (106). Our own recent studies depicted that following in vivo or in vitro blockade of glycolysis, the expression of IL-13 and IL-5 was significantly reduced (41). Whether this is also mediated through GAPDH remains to be determined.

High concentrations of extracellular lactate, a byproduct of glycolysis, has also been shown to reduce the CCL5-induced motility of CD4 T cells. This effect is mediated by the sodium lactate transporter Slc5a12 and has been proposed as a mechanism retaining effector cells at sites of inflammation (108). It has also been shown to potentiate CD8 T cell function (109). Whether these mechanisms play a role in Th2 cell function and the pathology of asthma remains to be shown.

In summary, while glycolysis appears to be important for effector cytokine production by T helper cells, Th2 cells in tissues appear enriched for pathways associated with lipid metabolism compared to other T helper cell subsets and naïve cells. This is typified by the expression of genes associated with fatty acid metabolism, the open chromatin state of Th2 cells at several key genes associated with lipid metabolism, and the requirement for PPAR-γ in mediating robust Th2 cell-mediated immune responses.

Extracellular ATP

ATP found in the extracellular environment operates as a potent DAMP due to its almost complete absence from healthy tissues and its quick release following cell damage (110). It is sensed via P2X and P2Y receptors, expressed throughout the immune system. It has been widely shown that levels of extracellular ATP are elevated in the bronchoalveolar lavage fluid (BALF) of asthmatic patients in comparison to healthy controls (111) and it is thought to induce migration of eosinophils and activation of mast cells in the lung and airways (112). Unlike Treg cells, Th2 cells appear to be relatively insensitive to cell death induced by extracellular ATP (113). Exposure of mice to inhaled allergens such as ovalbumin (OVA) results in an increase of ATP in the airways (111). Non-degradable forms of ATP, which cannot be metabolized by ectonucleases CD39 and CD73, are capable of breaking tolerance and inducing type 2 responses to inert antigens such as OVA (111). It can also be induced in airway epithelium in response to allergens such as the Cockroach allergen, Per a 10, or aeroallergens derived from Alternaria alternata. It can drive IL-33 release which further supports Th2 cell differentiation and metabolic reprogramming in situ (114, 115). Autocrine ATP is sensed via the P2Y₂ receptor, which increases intracellular Ca^{concentrations that in turn increase IL-33 release. Blockade of the P2Y}₂ receptor is sufficient to halt Th2 cell induction (115). ATP has also been shown to induce DCs that promote Th2 cell responses. Interestingly, CD39-deficient mice have defective Th2 cell responses to both OVA and HDM (116). In the absence of CD39, DCs in these mice have impaired purinergic receptor activity, appear less able to upregulate co-stimulatory molecules and exhibit defects in chemotaxis. These studies suggest an important inflammatory role for ATP in driving Th2 cell responses to a range of allergens.

Short Chain Fatty Acids (SCFAs)

The gut microbiome greatly influences the composition of metabolites that is in our circulation. One important immune regulatory product of fermenting bacteria in the intestines are SCFAs. SCFAs can be transported into cells via various receptors and have been shown to contribute to epigenetic modifications (117). SCFAs also bind to G-Protein Coupled Receptor 41 (GPR41, also known as FFAR3) and GPR43 (FFAR2) (118) and can modulate immune cell functions through these receptors. Typically, SCFAs have been shown to suppress inflammation and promote tolerance by various mechanisms. In line with this, mice fed a high fiber diet and hence with high circulating levels of SCFAs, have been shown to develop reduced airway inflammation in OVA/alum and HDM models of allergic airway disease. In one study, SCFAs appeared to suppress dendritic cell activation and migration through GPR41 (118). In another study, GPR41 was proposed to promote Treg cell IL-10 production, thereby suppressing allergic airway inflammation (119). Administration of a high-fiber or high-acetate diet in pregnant mice was also shown to reduce allergic airway disease in progeny, by promoting acetylation of the Foxp3 locus in Treg cells, highlighting the potent immune modulatory effects of these molecules (120). Studies of ILC2 have also shown that type 2 cytokine production and GATA3 expression may be dampened by SCFAs (121, 122). Despite the known anti-inflammatory function of SCFAs, a recent study of Th2 cells in people with eosinophilic esophagitis and in a mouse model of fungal infection revealed that SCFAs may also potentiate Th2 cell cytokine production (123). Thus, the impact of SCFAs on Th2 cell differentiation and function requires further investigation.

Glutamine

The conditionally essential amino acid glutamine is found at relatively high concentrations in the plasma and is capable of providing cells with a potential source of energy. However, under conditions of catabolic stress such as tissue damage or infection demand for glutamine rises with immune cells consuming particular high levels (124). Upon activation, T cells increase their uptake of glutamine 5–10-fold through the glutamine specific transporters SNAT-1/2 (124, 125). It serves as an important source of nitrogen and as an anapleurotic substrate for the TCA cycle and production of ribose in T cells (126–128). A lack of glutamine results in a failure for sustained proliferation and impairs cytokine release from T cells (125). Although glutamine plays an essential role in T cell activation, the addition of glutamine to the diet has been shown to favor Th1 cell responses over Th2 cells (129). Similarly, addition of high concentrations in vitro impairs Th2 cell differentiation in human PBMC cultures (130). This is at least in part due to the ability of high concentrations of glutamine to inhibit cytosolic phospholipase A2 (cPLA2), a key enzyme in releasing arachidonic acid from glycerophospholipids (131). This in turn provides the precursor molecules for a number of eicosanoids including well-known inflammatory mediators such as leukotrienes (LTs), prostaglandins and platelet-activating factor (PAF), which are important for Th2 cell functions. Thus, glutamine has the ability to regulate Th2 cell responses.

Indoamine 2,3-dioxygenase (IDO)

IDO is the rate-limiting enzyme required for tryptophan (TRP) metabolism (132). Within tissues such as the lung, IDO expression is high on epithelial cells and certain DC subpopulations (133). Given its constitutively high expression on Treg cells and cancer, IDO has been widely linked to immune suppression although some studies have indicated that it can in fact promote Th2 cell function. For instance it has been observed that 3-hyrdroxyanthranilic and quinolinic acids, metabolites of the KYN pathway, are capable of inducing apoptosis in Th1 cells without affecting Th2 cells (134). IDO expression by eosinophils is capable of inhibiting IFN-γ production by Th1 cells with no effect on Th2 cell function (135).

It has also been shown that IDO can potentiate Th2 cell cytokine production during in vitro differentiation of Th2 cells (133). In the context of airway inflammation, IDO-deficient mice appeared to have reduced Th2 cell responses and reduced levels of circulating IgE. Thus, IDO may aid in potentiating the polarization of Th2 cells and possibly inhibit bystander Th1 cells. Reduced expression of IDO during pregnancy results in enhanced ratios of Th1:Th2 cells (136). Interestingly, KYN-TRP levels are profoundly influenced by the composition of the gut microbiota via activation of AhR and TLRs in the host (137). Thus, regulation of TRP metabolism by IDO appears to promote Th2 cell responses.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Edited by: Hannes Stockinger, Medical University of Vienna, Austria

Reviewed by: Valerie Dardalhon, UMR5535 Institut de Génétique Moléculaire de Montpellier (IGMM), France; Paula M. Oliver, University of Pennsylvania, United States

*Correspondence: Jonathan M. Coquet es.ik@teuqoc.nahtanoj

This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology

†These authors have contributed equally to this work

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Edited by: Hannes Stockinger, Medical University of Vienna, Austria

Reviewed by: Valerie Dardalhon, UMR5535 Institut de Génétique Moléculaire de Montpellier (IGMM), France; Paula M. Oliver, University of Pennsylvania, United States

Received 2019 Jul 5; Accepted 2019 Sep 13.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Abstract

Upon activation, naïve CD4^{T cells differentiate into a number of specialized T helper (Th) cell subsets. Th2 cells are central players in immunity to helminths and are implicated in mediating the inflammatory pathology associated with allergies. The differentiation of Th2 cells is dependent on transcription factors such as GATA3 and STAT6, which prime Th2 cells for the secretion of interleukin- (IL-) 4, IL-5, and IL-13. Several lines of work now suggest that differentiating Th2 cells in the lymph node are potent IL-4 cytokine producers, but do not become competent IL-5- and IL-13-producing cells until after receiving cues from non-lymphoid tissue. It is evident that Th2 cells that enter tissues undergo considerable changes in chromatin architecture and gene expression, and that over this time, the metabolic requirements of these cells change considerably. Herein, we discuss the metabolic requirements of Th2 cells during their early and late differentiation, focusing on the impact of glucose and lipid metabolism, mTOR activation, the nuclear receptor PPAR-γ and several metabolites.}

Keywords: Th2, PPAR-γ, lipid metabolism, glycolysis, mTOR

Abstract

References

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. (1986) 136:2348. [[PubMed]
2. Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol. (2017) 18:121. 10.1038/nri.2017.118 [] [[PubMed]
3. Kopf M, Gros GL, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. (1993) 362:245–8. 10.1038/362245a0 [] [[PubMed]
4. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, et al. . Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. (2001) 167:6533. 10.4049/jimmunol.167.11.6533 [] [[PubMed]
5. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. (1992) 176:287–92. 10.1084/jem.176.1.287 ] [
6. Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. (1989) 245:308. 10.1126/science.2787531 [] [[PubMed]
7. Dabbagh K, Takeyama K, Lee H-M, Ueki IF, Lausier JA, Nadel JA. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J Immunol. (1999) 162:6233. [[PubMed]
8. Galli SJ, Starkl P, Marichal T, Tsai M. Mast cells and IgE in defense against venoms: possible “good side” of allergy?Allergol Int. (2016) 65:3–15. 10.1016/j.alit.2015.09.002 [] [[PubMed]
9. Paul WE, Zhu J. How are TH2-type immune responses initiated and amplified?Nat Rev Immunol. (2010) 10:225 10.1038/nri2735 ] [
10. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. (2015) 16:45. 10.1038/ni.3049 [] [[PubMed]
11. Masoli M, Fabian D, Holt S, Beasley R, Global initiative for asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. (2004) 59:469–78. 10.1111/j.1398-9995.2004.00526.x [] [[PubMed]
12. Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn's disease and ulcerative colitis show unique cytokine profiles. Cureus. (2017) 9:e1177. 10.7759/cureus.1177 ] [
13. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity. (1996) 4:313–9. 10.1016/S1074-7613(00)80439-2 [] [[PubMed]
14. Ouyang W, Löhning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, et al. . Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity. (2000) 12:27–37. 10.1016/S1074-7613(00)80156-9 [] [[PubMed]
15. Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, Sha WC, et al. . Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity. (1998) 9:745–55. 10.1016/S1074-7613(00)80671-8 [] [[PubMed]
16. Zhu J, Min B, Hu-Li J, Watson CJ, Grinberg A, Wang Q, et al Conditional deletion of Gata3 shows its essential function in TH1-TH2 responses. Nat Immunol. (2004) 5:1157–65. 10.1038/ni1128 [] [[PubMed][Google Scholar]
17. Zhang D-H, Yang L, Cohn L, Parkyn L, Homer R, Ray P, et al. . Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity. (1999) 11:473–82. 10.1016/S1074-7613(00)80122-3 [] [[PubMed]
18. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. (2015) 75:14–24. 10.1016/j.cyto.2015.05.010 ] [
19. Pai S-Y, Truitt ML, Ho IC. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci USA. (2004) 101:1993–8. 10.1073/pnas.0308697100 ] [
20. Lee HJ, Takemoto N, Kurata H, Kamogawa Y, Miyatake S, O'Garra A, et al. . GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp Med. (2000) 192:105–15. 10.1084/jem.192.1.105 ] [
21. Zhang D-H, Cohn L, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem. (1997) 272:21597–603. 10.1074/jbc.272.34.21597 [] [[PubMed]
22. Zheng W-P, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. (1997) 89:587–96. 10.1016/S0092-8674(00)80240-8 [] [[PubMed]
23. Ansel KM, Lee DU, Rao A. An epigenetic view of helper T cell differentiation. Nat Immunol. (2003) 4:616–23. 10.1038/ni0703-616 [] [[PubMed]
24. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of TH2 differentiation and Il4 locus accessibility. Ann Rev Immunol. (2006) 24:607–56. 10.1146/annurev.immunol.23.021704.115821 [] [[PubMed]
25. Lee GR, Fields PE, Griffin TJ, Flavell RA. Regulation of the Th2 cytokine locus by a locus control region. Immunity. (2003) 19:145–53. 10.1016/S1074-7613(03)00179-1 [] [[PubMed]
26. Lee GR, Kim ST, Spilianakis CG, Fields PE, Flavell RA. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity. (2006) 24:369–79. 10.1016/j.immuni.2006.03.007 [] [[PubMed]
27. Wei G, Abraham BJ, Yagi R, Jothi R, Cui K, Sharma S, et al. . Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. Immunity. (2011) 35:299–311. 10.1016/j.immuni.2011.08.007 ] [
28. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. (2006) 16:3–10. 10.1038/sj.cr.7310002 [] [[PubMed]
29. Nicholas vP, Shiau-Choot T, Melanie P, Mali C, Debbie S, Joanna R, et al. . In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation. Proc Natl Acad Sci USA. (2008) 105:12423–8. 10.1073/pnas.0806372105 ] [
30. Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. J Immunol. (1990) 145:1127. [[PubMed]
31. Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 activation plays a critical role in Th2 differentiation. Immunity. (2003) 19:739–48. 10.1016/S1074-7613(03)00292-9 [] [[PubMed]
32. Kagami S-i, Nakajima H, Kumano K, Suzuki K, Suto A, Imada K, et al. . Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood. (2000) 95:1370. 10.1016/S0091-6749(00)91471-4 [] [[PubMed]
33. Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, et al. . The transcription factor STAT3 is required for T helper 2 cell development. Immunity. (2011) 34:39–49. 10.1016/j.immuni.2010.12.013 ] [
34. Ahyi A-NN, Chang H-C, Dent AL, Nutt SL, Kaplan MH. IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines. J Immunol. (2009) 183:1598. 10.4049/jimmunol.0803302 ] [
35. Kim JI, Ho IC, Grusby MJ, Glimcher LH. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity. (1999) 10:745–51. 10.1016/S1074-7613(00)80073-4 [] [[PubMed]
36. Li-Weber M, Giaisi M, Baumann S, Pálfi K, Krammer PH. NF-κB synergizes with NF-AT and NF-IL6 in activation of the IL-4 gene in T cells. Eur J Immunol. (2004) 34:1111–8. 10.1002/eji.200324687 [] [[PubMed]
37. Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine. (2015) 75:25–37. 10.1016/j.cyto.2015.05.008 ] [
38. King IL, Mohrs M. IL-4-producing CD4+ T cells in reactive lymph nodes during helminth infection are T follicular helper cells. J Exp Med. (2009) 206:1001–7. 10.1084/jem.20090313 ] [
39. Liang H-E, Reinhardt RL, Bando JK, Sullivan BM, Ho IC, Locksley RM. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol. (2011) 13:58–66. 10.1038/ni.2182 ] [
40. Yusuf I, Kageyama R, Monticelli L, Johnston RJ, Ditoro D, Hansen K, et al. . Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150). J Immunol. (2010) 185:190–202. 10.4049/jimmunol.0903505 ] [
41. Tibbitt CA, Stark JM, Martens L, Ma J, Mold JE, Deswarte K, et al. . Single-cell RNA sequencing of the T helper cell response to house dust mites defines a distinct gene expression signature in airway Th2 cells. Immunity. (2019) 51:1–16. 10.1016/j.immuni.2019.05.014 [] [[PubMed]
42. Van Dyken SJ, Nussbaum JC, Lee J, Molofsky AB, Liang H-E, Pollack JL, et al. . A tissue checkpoint regulates type 2 immunity. Nat Immunol. (2016) 17:1381–7. 10.1038/ni.3582 ] [
43. Lawrence RA, Gray CA, Osborne J, Maizels RM. Nippostrongylus brasiliensis: cytokine responses and nematode expulsion in normal and IL-4-deficient mice. Exp Parasitol. (1996) 84:65–73. 10.1006/expr.1996.0090 [] [[PubMed]
44. Mandel TE, Phipps RP, Abbot AP, Tew JG. Long-term antigen retention by dendritic cells in the popliteal lymph node of immunized mice. Immunology. (1981) 43:353–62.
45. Urban JF, Maliszewski CR, Madden KB, Katona IM, Finkelman FD. IL-4 treatment can cure established gastrointestinal nematode infections in immunocompetent and immunodeficient mice. J Immunol. (1995) 154:4675. [[PubMed]
46. Bancroft AJ, McKenzie ANJ, Grencis RK. A Critical Role for IL-13 in resistance to intestinal nematode infection. J Immunol. (1998) 160:3453. [[PubMed]
47. O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. (2016) 16:553–65. 10.1038/nri.2016.70 ] [
48. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Ann Rev Immunol. (2013) 31:259–83. 10.1146/annurev-immunol-032712-095956 ] [
49. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. . The CD28 signaling pathway regulates glucose metabolism. Immunity. (2002) 16:769–77. 10.1016/S1074-7613(02)00323-0 [] [[PubMed]
50. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. (2007) 18:1437–46. 10.1091/mbc.e06-07-0593 ] [
51. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. . Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. (2011) 186:3299–303. 10.4049/jimmunol.1003613 ] [
52. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. . HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 cells. J Exp Med. (2011) 208:1367–76. 10.1084/jem.20110278 ] [
53. Wang R, Dillon Christopher P, Shi Lewis Z, Milasta S, Carter R, Finkelstein D, et al. . The transcription factor myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. (2011) 35:871–82. 10.1016/j.immuni.2011.09.021 ] [
54. Peng M, Yin N, Chhangawala S, Xu K, Leslie CS, Li MO. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science. (2016) 354:481. 10.1126/science.aaf6284 ] [
55. Lochner M, Berod L, Sparwasser T. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. (2015) 36:81–91. 10.1016/j.it.2014.12.005 [] [[PubMed]
56. Dumitru C, Kabat AM, Maloy KJ. Metabolic adaptations of CD4(+) T cells in inflammatory disease. Front Immunol. (2018) 9:540. 10.3389/fimmu.2018.00540 ] [
57. Saxton RA, Sabatini DM. mTOR Signaling in growth, metabolism, and disease. Cell. (2017) 168:960–76. 10.1016/j.cell.2017.02.004 ] [
58. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol. (2014) 14:435–46. 10.1038/nri3701 ] [
59. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. . Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity. (2010) 32:743–53. 10.1016/j.immuni.2010.06.002 ] [
60. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, et al. . PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. Cell Rep. (2012) 1:360–73. 10.1016/j.celrep.2012.02.007 [] [[PubMed]
61. Sun I-H, Oh M-H, Zhao L, Patel CH, Arwood ML, Xu W, et al. . mTOR complex 1 signaling regulates the generation and function of central and effector foxp3^{regulatory T cells}. J Immunol. (2018) 201:481–92. 10.4049/jimmunol.1701477 ] [
62. Yang K, Shrestha S, Zeng H, Karmaus PWF, Neale G, Vogel P, et al. . T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity. (2013) 39:1043–56. 10.1016/j.immuni.2013.09.015 ] [
63. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. . The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. (2011) 12:295–303. 10.1038/ni.2005 ] [
64. Seki Y-I, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, et al. . Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA. (2002) 99:13003–8. 10.1073/pnas.202477099 ] [
65. Heikamp EB, Patel CH, Collins S, Waickman A, Oh M-H, Sun I-H, et al. . The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nat Immunol. (2014) 15:457–64. 10.1038/ni.2867 ] [
66. Yang J-Q, Kalim KW, Li Y, Zhang S, Hinge A, Filippi M-D, et al. . RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. (2016) 137:231–45.e4. 10.1016/j.jaci.2015.05.004 ] [
67. Ricciardi S, Manfrini N, Alfieri R, Calamita P, Crosti MC, Gallo S, et al The translational machinery of human CD4+ T cells is poised for activation and controls the switch from quiescence to metabolic remodeling. Cell Metab. (2018) 28:895–906.e5. 10.1016/j.cmet.2018.08.009 ] [[Google Scholar]
68. Cretenet G, Clerc I, Matias M, Loisel S, Craveiro M, Oburoglu L, et al. . Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions. Sci Rep. (2016) 6:24129. 10.1038/srep24129 ] [
69. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. . The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. (2014) 20:61–72. 10.1016/j.cmet.2014.05.004 ] [
70. Finlay DK. Regulation of glucose metabolism in T cells: new insight into the role of phosphoinositide 3-kinases. Front Immunol. (2012) 3:247. 10.3389/fimmu.2012.00247 ] [
71. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. . SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. (2008) 8:224–36. 10.1016/j.cmet.2008.07.007 ] [
72. Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. . De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. (2014) 20:1327. 10.1038/nm.3704 [] [[PubMed]
73. Angela M, Endo Y, Asou HK, Yamamoto T, Tumes DJ, Tokuyama H, et al. . Fatty acid metabolic reprogramming via mTOR-mediated inductions of PPARγ directs early activation of T cells. Nat Commun. (2016) 7:13683. 10.1038/ncomms13683 ] [
74. Park H-J, Kim D-H, Choi J-Y, Kim W-J, Kim JY, Senejani AG, et al. . PPARγ negatively regulates T cell activation to prevent follicular helper T cells and germinal center formation. PLoS ONE. (2014) 9:e99127. 10.1371/journal.pone.0099127 ] [
75. Ballesteros-Tato A, Randall TD, Lund FE, Spolski R, Leonard WJ, León B. T Follicular helper cell plasticity shapes pathogenic T helper 2 cell-mediated immunity to inhaled house dust mite. Immunity. (2016) 44:259–73. 10.1016/j.immuni.2015.11.017 ] [
76. Coquet Jonathan M, Schuijs Martijn J, Smyth Mark J, Deswarte K, Beyaert R, Braun H, et al. . Interleukin-21-producing CD4+ T cells promote type 2 immunity to house dust mites. Immunity. (2015) 43:318–30. 10.1016/j.immuni.2015.07.015 [] [[PubMed]
77. Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. (2019) 50:975–91. 10.1016/j.immuni.2019.03.018 [] [[PubMed]
78. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. (2009) 15:410. 10.1038/nm.1946 ] [
79. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, et al. . Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. (2002) 169:5315. 10.4049/jimmunol.169.9.5315 [] [[PubMed]
80. Besnard A-G, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol. (2011) 41:1675–86. 10.1002/eji.201041033 [] [[PubMed]
81. Constant SL, Brogdon JL, Piggott DA, Herrick CA, Visintin I, Ruddle NH, et al. . Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest. (2002) 110:1441–8. 10.1172/JCI200216109 ] [
82. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. (2009) 123:1047–54. 10.1016/j.jaci.2009.02.026 ] [
83. Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy. (2009) 39:798–806. 10.1111/j.1365-2222.2009.03241.x ] [
84. Ito T, Wang Y-H, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. . TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. (2005) 202:1213–23. 10.1084/jem.20051135 ] [
85. Chu DK, Llop-Guevara A, Walker TD, Flader K, Goncharova S, Boudreau JE, et al. . IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol. (2013) 131:187–200.e8. 10.1016/j.jaci.2012.08.002 [] [[PubMed]
86. Shih H-Y, Sciumè G, Mikami Y, Guo L, Sun H-W, Brooks SR, et al. . Developmental acquisition of regulomes underlies innate lymphoid cell functionality. Cell. (2016) 165:1120–33. 10.1016/j.cell.2016.04.029 ] [
87. Gury-BenAri M, Thaiss CA, Serafini N, Winter DR, Giladi A, Lara-Astiaso D, et al. . The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. Cell. (2016) 166:1231–46.e13. 10.1016/j.cell.2016.07.043 [] [[PubMed]
88. Wilhelm C, Harrison OJ, Schmitt V, Pelletier M, Spencer SP, Urban JF, Jr, et al. . Critical role of fatty acid metabolism in ILC2-mediated barrier protection during malnutrition and helminth infection. J Exp Med. (2016) 213:1409–18. 10.1084/jem.20151448 ] [
89. Robinette ML, Fuchs A, Cortez VS, Lee JS, Wang Y, Durum SK, et al. . Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat Immunol. (2015) 16:306–17. 10.1038/ni.3094 ] [
90. Björklund ÅK, Forkel M, Picelli S, Konya V, Theorell J, Friberg D, et al. . The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing. Nat Immunol. (2016) 17:451. 10.1038/ni.3368 [] [[PubMed]
91. Chen T, Tibbitt CA, Feng X, Stark JM, Rohrbeck L, Rausch L, et al. . PPAR-γ promotes type 2 immune responses in allergy and nematode infection. Sci Immunol. (2017) 2:eaal5196. 10.1126/sciimmunol.aal5196 [] [[PubMed]
92. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metab. (2014) 25:293–302. 10.1016/j.tem.2014.04.001 ] [
93. Nobs SP, Natali S, Pohlmeier L, Okreglicka K, Schneider C, Kurrer M, et al. . PPARγ in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation. J Exp Med. (2017) 214:3015–35. 10.1084/jem.20162069 ] [
94. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. . PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. (2013) 19:557–66. 10.1038/nm.3159 ] [
95. Daniel B, Nagy G, Czimmerer Z, Horvath A, Hammers DW, Cuaranta-Monroy I, et al. . The nuclear receptor PPARγ controls progressive macrophage polarization as a ligand-insensitive epigenomic ratchet of transcriptional memory. Immunity. (2018) 49:615–26.e6. 10.1016/j.immuni.2018.09.005 ] [
96. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. . Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. (2007) 447:1116–20. 10.1038/nature05894 ] [
97. Szanto A, Balint BL, Nagy ZS, Barta E, Dezso B, Pap A, et al. . STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells. Immunity. (2010) 33:699–712. 10.1016/j.immuni.2010.11.009 ] [
98. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. . Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. (2006) 4:13–24. 10.1016/j.cmet.2006.05.011 ] [
99. Micossé C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, et al. . Human “TH9” cells are a subpopulation of PPAR-γ+ TH2 cells. Sci Immunol. (2019) 4:eaat5943. 10.1126/sciimmunol.aat5943 [] [[PubMed]
100. Henriksson J, Chen X, Gomes T, Ullah U, Meyer KB, Miragaia R, et al. . Genome-wide CRISPR screens in T helper cells reveal pervasive crosstalk between activation and differentiation. Cell. (2019) 176:882–96.e18. 10.1016/j.cell.2018.11.044 ] [
101. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activatorsa. Ann N Y Acad Sci. (1996) 804:266–75. 10.1111/j.1749-6632.1996.tb18621.x [] [[PubMed]
102. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Ann Rev Biochem. (2008) 77:289–312. 10.1146/annurev.biochem.77.061307.091829 [] [[PubMed]
103. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell Metab. (2013) 18:153–61. 10.1016/j.cmet.2013.05.017 ] [
104. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor γ and β-catenin signaling during adipogenesis: a glycogen synthase kinase 3β phosphorylation-defective mutant of β-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem. (2004) 279:45020–7. 10.1074/jbc.M407050200 [] [[PubMed]
105. Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol Endocrinol Metab. (2015) 309:E691–714. 10.1152/ajpendo.00297.2015 [] [[PubMed]
106. Chang C-H, Curtis JD, Maggi LB, Jr, Faubert B, Villarino AV, O'Sullivan D, et al. . Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. (2013) 153:1239–51. 10.1016/j.cell.2013.05.016 ] [
107. Chang C-H, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. . Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. (2015) 162:1229–41. 10.1016/j.cell.2015.08.016 ] [
108. Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, et al. . Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol. (2015) 13:e1002202. 10.1371/journal.pbio.1002202 ] [
109. Rundqvist H, Veliça P, Barbieri L, Gameiro PA, Cunha PP, Gojkovic M, et al Lactate potentiates differentiation and expansion of cytotoxic T cells. bioRxiv. (2019) 571745 10.2139/ssrn.3411249 [[PubMed][Google Scholar]
110. Willart MAM, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy. (2009) 39:12–9. 10.1111/j.1365-2222.2008.03118.x [] [[PubMed]
111. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MAM, Muskens F, et al. . Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med. (2007) 13:913. 10.1038/nm1617 [] [[PubMed]
112. Kobayashi T, Soma T, Noguchi T, Nakagome K, Nakamoto H, Kita H, et al. . ATP drives eosinophil effector responses through P2 purinergic receptors. Allergol Int. (2015) 64:S30–6. 10.1016/j.alit.2015.04.009 ] [
113. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4 +CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol. (2005) 175:3075–83. 10.4049/jimmunol.175.5.3075 [] [[PubMed]
114. Kale SL, Agrawal K, Gaur SN, Arora N. Cockroach protease allergen induces allergic airway inflammation via epithelial cell activation. Sci Rep. (2017) 7:42341. 10.1038/srep42341 ] [
115. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. (2011) 186:4375–87. 10.4049/jimmunol.1003020 ] [
116. Idzko M, Ayata CK, Müller T, Dürk T, Grimm M, Baudiß K, et al. . Attenuated allergic airway inflammation in Cd39 null mice. Allergy. (2013) 68:472–80. 10.1111/all.12119 ] [[Google Scholar]
117. Krautkramer KA, Kreznar JH, Romano KA, Vivas EI, Barrett-Wilt GA, Rabaglia ME, et al. . Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol Cell. (2016) 64:982–92. 10.1016/j.molcel.2016.10.025 ] [
118. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. . Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. (2014) 20:159. 10.1038/nm.3444 [] [[PubMed]
119. Zaiss MM, Rapin A, Lebon L, Dubey LK, Mosconi I, Sarter K, et al. . The intestinal microbiota contributes to the ability of helminths to modulate allergic inflammation. Immunity. (2015) 43:998–1010. 10.1016/j.immuni.2015.09.012 ] [
120. Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, et al. . Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat Commun. (2015) 6:7320. 10.1038/ncomms8320 [] [[PubMed]
121. Thio CL-P, Chi P-Y, Lai AC-Y, Chang Y-J. Regulation of type 2 innate lymphoid cell–dependent airway hyperreactivity by butyrate. J Allergy Clin Immunol. (2018) 142:1867–83.e12. 10.1016/j.jaci.2018.02.032 [] [[PubMed]
122. Wang J, Wen L, Wang Y, Chen F. Therapeutic effect of histone deacetylase inhibitor, sodium butyrate, on allergic rhinitis in vivo. DNA Cell Biol. (2016) 35:203–8. 10.1089/dna.2015.3037 [] [[PubMed]
123. Wen T, Aronow BJ, Rochman Y, Rochman M, Kc K, Dexheimer PJ, et al. . Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. J Clin Invest. (2019) 129:2014–28. 10.1172/JCI125917 ] [
124. Ren W, Liu G, Yin J, Tan B, Wu G, Bazer FW, et al Amino-acid transporters in T-cell activation and differentiation. Cell Death Dis. (2017) 8:e2655 10.1038/cddis.2016.222 ] [[Google Scholar]
125. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. . Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. (2010) 185:1037–44. 10.4049/jimmunol.0903586 ] [
126. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. (2016) 16:619–34. 10.1038/nrc.2016.71 ] [
127. Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, et al. . Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther. (2014) 351:298–307. 10.1124/jpet.114.218099 ] [
128. Kovacevic Z, McGivan JD. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev. (1983) 63:547–605. 10.1152/physrev.1983.63.2.547 [] [[PubMed]
129. Caris AV, Lira FS, de Mello MT, Oyama LM, dos Santos RVT. Carbohydrate and glutamine supplementation modulates the Th1/Th2 balance after exercise performed at a simulated altitude of 4500 m. Nutrition. (2014) 30:1331–6. 10.1016/j.nut.2014.03.019 [] [[PubMed]
130. Chang W-K, Yang KD, Shaio M-F. Effect of glutamine on Th1 and Th2 cytokine responses of human peripheral blood mononuclear cells. Clin Immunol. (1999) 93:294–301. 10.1006/clim.1999.4788 [] [[PubMed]
131. Ko HM, Kang NI, Kim YS, Lee YM, Jin ZW, Jung YJ, et al Glutamine preferentially inhibits T-helper type 2 cell-mediated airway inflammation and late airway hyperresponsiveness through the inhibition of cytosolic phospholipase A2 activity in a murine asthma model. Clin Exp Allergy. (2008) 38:357–64. 10.1111/j.1365-2222.2007.02900.x [] [[PubMed][Google Scholar]
132. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. (2013) 34:137–43. 10.1016/j.it.2012.10.001 ] [
133. Xu H, Zhang G-X, Ciric B, Rostami A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett. (2008) 121:1–6. 10.1016/j.imlet.2008.08.008 ] [
134. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. . T cell apoptosis by tryptophan catabolism. Cell Death Differ. (2002) 9:1069–77. 10.1038/sj.cdd.4401073 [] [[PubMed]
135. Odemuyiwa SO, Ghahary A, Li Y, Puttagunta L, Lee JE, Musat-Marcu S, et al. . Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol. (2004) 173:5909. 10.4049/jimmunol.173.10.5909 [] [[PubMed]
136. Clark DA, Blois S, Kandil J, Handjiski B, Manuel J, Arck PC. Reduced uterine indoleamine 2,3-dioxygenase versus increased Th1/Th2 cytokine ratios as a basis for occult and clinical pregnancy failure in mice and humans. Am J Reprod Immunol. (2005) 54:203–16. 10.1111/j.1600-0897.2005.00299.x [] [[PubMed]
137. Van der Leek AP, Yanishevsky Y, Kozyrskyj AL. The kynurenine pathway as a novel link between allergy and the gut microbiome. Front Immunol. (2017) 8:1374. 10.3389/fimmu.2017.01374 ] [
138. Cottrell L, Neal WA, Ice C, Perez MK, Piedimonte G. Metabolic abnormalities in children with asthma. Am J Respir Crit Care Med. (2011) 183:441–8. 10.1164/rccm.201004-0603OC ] [
139. Serafino-Agrusa L, Spatafora M, Scichilone N. Asthma and metabolic syndrome: current knowledge and future perspectives. World J Clin Cases. (2015) 3:285–92. 10.12998/wjcc.v3.i3.285 ] [
140. Del Giacco SR, Firinu D, Bjermer L, Carlsen K-H. Exercise and asthma: an overview. Eur Clin Respir J. (2015) 2:27984. 10.3402/ecrj.v2.27984 ] [
141. Banno A, Reddy AT, Lakshmi SP, Reddy RC. PPARs: key regulators of airway inflammation and potential therapeutic targets in asthma. Nucl Receptor Res. (2018) 5:101306. 10.11131/2018/101306 ] [
142. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol. (2006) 533:101–9. 10.1016/j.ejphar.2005.12.048 [] [[PubMed]
143. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. (2003) 139:163–71. 10.1038/sj.bjp.0705232 ] [
144. Woerly G, Honda K, Loyens M, Papin J-P, Auwerx J, Staels B, et al. . Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med. (2003) 198:411–21. 10.1084/jem.20021384 ] [
145. Anderson JR, Mortimer K, Pang L, Smith KM, Bailey H, Hodgson DB, et al. . Evaluation of the PPAR-γ agonist pioglitazone in mild asthma: a double-blind randomized controlled trial. PLoS ONE. (2016) 11:e0160257. 10.1371/journal.pone.0160257 ] [
146. Kaler M, Barochia AV, Weir NA, Cuento RA, Stylianou M, Roth MJ, et al. . A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma. J Allergy Clin Immunol. (2017) 140:1716–8. 10.1016/j.jaci.2017.05.033 ] [
147. Bisgaard H, Stokholm J, Chawes BL, Vissing NH, Bjarnadóttir E, Schoos A-MM, et al. . Fish oil–derived fatty acids in pregnancy and wheeze and asthma in offspring. N Eng J Med. (2016) 375:2530–9. 10.1056/NEJMoa1503734 [] [[PubMed]
148. Guilleminault L, Williams EJ, Scott HA, Berthon BS, Jensen M, Wood LG. Diet and asthma: is it time to adapt our message?Nutrients. (2017) 9:1227. 10.3390/nu9111227 ] [
149. Weickert MO, Pfeiffer AFH. Impact of dietary fiber consumption on insulin resistance and the prevention of type 2 diabetes. J Nutr. (2018) 148:7–12. 10.1093/jn/nxx008 [] [[PubMed]